Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Aihol Corporation currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner, reflecting a highly specific focus for the company's current patent filings. The use of 1 distinct art unit indicates that the pharmaceutical or biological technology is being reviewed by a single specialized division. This arrangement simplifies the prosecution by avoiding the need to navigate multiple art unit standards.
MAHADEVAN, JANAKI ANANTH is the busiest examiner for this portfolio, holding 1 busiest examiner pending action. As the total volume is 1 pending office action, MAHADEVAN, JANAKI ANANTH is the only examiner currently evaluating the company's intellectual property. This relationship between the action and the examiner centralizes the entire prosecution process. The 1 busiest examiner pending action is the only active hurdle identified in the company's current portfolio.
The data shows a concentrated effort within the Biotechnology & Pharmaceuticals field, governed by 1 distinct examiner and 1 distinct art unit. For practitioners, this means the prosecution strategy can be entirely focused on the requirements of the assigned examiner. With only 1 pending office action, the company's immediate patent prospects depend on the resolution of this case. This profile indicates a streamlined and targeted approach to securing intellectual property within the assigned art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MAHADEVAN, JANAKI ANANTH | 1 | — | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18365528 | HYALURONAN-NIMESULIDE CONJUGATE FOR TREATING LOCALLY ADVANCED OR METASTATIC TUMORS | MAHADEVAN, JANAKI ANANTH | 1693 | §103Other | Non-Final OA | 22d | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial